GoodFellas Big Board Catalyst and Chart Plays

[Norm]

IBIO - looking for a quick 10 percent pop or more today. need to meet requirements or get extension oct 16th

Entry into a Material Definitive Agreement


Item 1.01 Entry into a Material Definitive Agreement
Amendment of TTA between iBio and Fraunhofer

We and Fraunhofer, USA, Inc. ("Fraunhofer"), our collaborative research and development partner, entered into a new agreement effective June 30, 2013 (the "2013 Amendment") that has the effect of further amending the terms of the Technology Transfer Agreement which we and Fraunhofer originally entered into effective as of January 1, 2004 (as previously amended, the "TTA"). The 2013 Amendment, which is intended to better align the mutual interests of iBio and Fraunhofer, has the following effects:

? Our liabilities to Fraunhofer in the amount of approximately $2,863,000 as of June 30, 2013 were released and terminated.

? The term of the TTA was extended by one year and will now expire on December 31, 2015.

? Our obligation under the TTA, prior to the 2013 Amendment, to make three further time-based $1,000,000 payments, on April 2 and November 2, 2013 and April 2, 2014 ("Guaranteed Annual Payments") was terminated and replaced with an obligation to engage Fraunhofer in iBio selected and directed project specific development activities, priced according to a mutually-agreed fair market formula, in an aggregate amount not less than $3,000,000 prior to December 31, 2015. We believe that our right to select and direct specific projects will improve the efficiency of our product development activities and that the extension of the period over which this commitment must be fulfilled will enhance our ability to manage our cash outflow.

? We terminated and released Fraunhofer from the obligation to make further financial contributions toward the enhancement, improvement and expansion of our technology in an amount at least equal to the Guaranteed Annual Payments, because we believe our technology development phase is completed and now are focusing on product development. Additionally, we terminated and released Fraunhofer from the obligation to further reimburse us for certain past and future patent related expenses.